Psilocybin, a psychedelic compound, significantly enhances serotonin levels, influencing neurotransmitter receptor mechanisms and behavior. In a study involving 150 participants, 70% reported improved mood and reduced anxiety after psilocybin administration. Mescaline, another tryptamine, exhibited similar effects, with 65% of 120 subjects noting increased emotional well-being. The biochemistry of these substances reveals their ability to stimulate the production of 5-hydroxytryptophan, impacting tryptophan hydroxylase activity. These findings underscore the potential of psychedelics in internal medicine and endocrinology for mental health treatment.
A randomized controlled trial will test whether a mindfulness mobile app can improve mental health in pregnant women. The study will enroll 360 prenatal women from Mater Mothers' Hospital, assigning them to either use the app or receive usual care. Over 11 months, researchers will measure changes in postnatal depression, mother-infant bonding, and quality of life. A cost-effectiveness analysis will also be performed. Some participants will provide feedback in focus groups. Previous research suggests mindfulness can reduce stress, anxiety, depression, and sleep problems during pregnancy. The intervention carries low risk and may benefit women who cannot attend in-person appointments due to distance, cost, time, or health issues.